CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

November 15, 2027

Study Completion Date

November 15, 2028

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
BIOLOGICAL

GPC3-CART cells

"Phase 1: Dose escalation (3+3): Dose 1 (1 × 10\^6 cells/kg) with or without FC regimen, Dose 2 (3 × 10\^6 cells/kg), Dose 3 (6 × 10\^6 cells/kg).~Phase 2: Dose at RP2D."

DRUG

Fludarabine Phosphate for Injection

Administered intravenously at a dose of 20-30 mg/m²/day on days -5, -4, and -3.

DRUG

Cyclophosphamide for Injection

Administered intravenously at a dose of 300-500 mg/m²/day on days -5, -4, and -3.

Trial Locations (1)

100853

Biotherapeutic Department of Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER

NCT06641453 - CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter